Systematic Review of Shengmai Injection for Cardiotoxicity Induced by Anthracyclines

Abstract

Abstract: ObjectiveTo explore the efficiency of Shengmai injection for cardiotoxicity in tumor patients induced by Anthracyclines. MethodsWe systematically retrieved the randomized controlled trials(RCTs) which were designed for Shengmai injection for cardiotoxicity in tumor patients induced by Anthracyclines.The three researchers selected the references according to the inclusion criterion, then appraised them critically and conducted meta-analysis. ResultsSix RCTs were included at last with 615 patitents, 307 in the experimental group and 308 in the control group.The two groups have statistically significant differences in every outcome we have designed: rate of abnormal electrocardiogram[RR=0.38, 95%CI(0.27,0.54), P<0.00001], change of EF[MD=-2.50, 95%CI(-3.83,-1.18), P=0.0002], change of LVDd[MD=-0.79,95%CI(-0.93,-0.66),P<0.00001], change of LVDs[MD=-0.58,95%CI(-0.82,-0.35),P<0.00001], change of FS[MD=-3.02,95%CI(-5.02,-1.01),P =0.003]. ConclusionOn current evidence, Shengmai injection is probably effective for the prevention and treatment of cardiotoxicity in tumor patients induced by Anthracyclines. However, more high quality clinical trials are needed to confirm this.

Key words: Shengmai, Anthracyclines, antitumor, cardiotoxicity, systematic review

YANG Min, LU Jing, MOU Jin-jin, XU Ting. Systematic Review of Shengmai Injection for Cardiotoxicity Induced by Anthracyclines[J]. Chinese Journal of Pharmacovigilance, 2012, 9(11): 666-669.

References

[1] Octavia Y,Tocchetti C G,Gabrielson K L,et al.Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies[J].Journal of Molecular and Cellular Cardiology,2012,52(6):1213-1215.
[2] Asensio-López MC,Lax A,Pascual-Figal DA,et al.Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of theadiponectin cardiac system[J].Free Radical Biology & Medicine,2011,51(10):1861-1871.
[3] Chatterjee K,Zhang J P,Rong T,et al.Vincristine attenuates doxoru-
bicin cardiotoxicity[J].Biochemical and Biophysical Research Communications,2008,373(4):555-560.
[4] Tokarska-Schlattner M, Zaugg M,Zuppinger C.New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics[J].Journal of Molecular and Cellular Cardiology,2006,
41(3):389-405.
[5] 王睿,徐长庆.阿霉素心脏毒性作用机制研究进展[J].齐齐哈尔医学院学报,2006,27(10):1221-1222.
[6] Beer E L,Bottone A E,Voest E E.Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review[J].European Journal of Pharmacology, 2001,415(1):1-11.
[7] 祝淑兰,刘巧云,白玉贤.阿霉素在临床应用中心脏毒性的研究[J].医药导报,1997,16(6):271-272.
[8] 胡欣, 李光明,任大成,等.阿霉素持续静脉注射与静脉注射给药的心脏毒性[J].实用癌症杂志,2009,24(3):306-308.
[9] 覃永安.生脉注射液的抗心律失常作用[J].中国现代医生,2008,
46(28):27-31.
[10] 邵迴龙, 张红明,张新奇,等.生脉注射液治疗老年慢性心力衰竭疗效的观察[J].解放军保健医学杂志,2006,8(4):216-217.
[11] 于晨.人参皂苷对心血管系统药理作用的研究[J].天津药学,2010,
22(4):45-47.
[12] 王天成, 张宏艳.人参皂甙抗心律失常作用研究进展[J].中国心脏起搏与心电生理杂志,2004,18(4):309-310.
[13] 孙健,蔡淼.山麦冬的化学成分及药理作用研究进展[J].中国药物警戒,2010,7(11):681-683.
[14] 刘威,张茜,张成义.五味子对心血管系统作用的研究[J].北华大学学报,2011,12(1):47-49.
[15] 宁莉.生脉注射液治疗阿霉素引起的心肌损害疗效观察[J].丹东医药,2007,15(6):19-20.
[16] 王瑞芹,解英,赵素珍.生脉注射液防治阿霉素相关性心脏毒性的临床观察[J].中西医结合心脑血管病杂志,2006,4(12):1092-
1093.
[17] 杨秀丽.生脉注射液预防多柔比星相关性心脏毒性反应的临床观察[J].中国医药指南, 2008,6(15):203-205.
[18] 张益康,何微波,张红,等.生脉注射液预防阿霉素急性心脏毒性40例疗效观察[J].中国中医急症, 2007,16(9):1082-1083.
[19] 张勇,武海明,马华.生脉注射液对乳腺癌表阿霉素多程化疗心脏毒性的作用研究[J].中西医结合心脑血管病杂志,2009,7(9):1030-1031.
[20] 章杰.生脉注射液在恶性肿瘤患者阿霉素化疗中的心肌保护作用[J].光明中医,2011,26(3):530.
[21] 董建红,张燕,苏喜改,等.参麦注射液联合香丹注射液预防蒽环类化疗药物所致心脏毒性的临床观察[J].现代中西医结合杂志,
2007,16(2):177-178.
[22] 杨莉,王亚非,姚祖培,等.中药方预防蒽环类化疗药物急性心脏毒性反应的临床研究[J].南京医科大学学报(自然科学版),2010,
30(10):1435-1438.